Analytical Data
-
基因名
IL-17A
- Application
-
别名
(IL-17)(IL-17A)(Cytotoxic T-lymphocyte-associated antigen 8)(CTLA-8)
-
种属
Rat
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE. as determined by SDS-PAGE.
-
蛋白编号
Q61453
-
表达区间
18-150aa
-
分子量
21.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine primarily produced by a subset of T cells known as Th17 cells. It plays a crucial role in immune responses against extracellular pathogens and is implicated in various autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. The significance of IL-17A in modulating inflammation has spurred extensive research into its biological functions and potential therapeutic applications. Recombinant IL-17A proteins have been developed to better understand its signaling pathways and interactions with other immune components. These proteins serve as valuable tools for exploring the mechanisms underlying IL-17A-related pathologies and for identifying novel therapeutic targets. Moreover, the investigation of IL-17A-recombinant proteins has paved the way for the development of monoclonal antibodies that inhibit IL-17A activity, which have shown promise in clinical settings. By blocking IL-17A signaling, these agents can effectively reduce inflammation and improve outcomes for patients suffering from autoimmune diseases. Continuing research on IL-17A and its recombinant forms is essential not only for elucidating its role in immune regulation but also for advancing therapeutic strategies aimed at mitigating the detrimental effects of excessive IL-17A activity in various inflammatory conditions.
